Evolving <scp>TRALI</scp> risk across apheresis and whole blood platelet products in the United States: An 18‐year American Red Cross hemovigilance analysis

Current mitigation strategies, which are not required for whole blood derived platelets in the United States, have substantially reduced TRALI risk from apheresis platelets. If whole blood-pooled platelets production in the United States increases, consideration should be given to the addition of mitigation strategies-such as male-predominant pooling and donor antibody screening-to align their safety profile.